The meeting focuses on biomarkers (neurology and psychiatry), precision psychiatry, digital health technologies (DHTs), regulatory science, and innovative trial designs for rare diseases, psychiatry, and neurology.  It gathers together professionals from academia, the pharmaceutical industry, and government or regulatory agencies (such as the FDA).